ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК И ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК: ВНИМАНИЕ К ОТДАЛЕННЫМ НЕОНКОЛОГИЧЕСКИМ ИСХОДАМ
https://doi.org/10.24884/1561-6274-2012-16-4-94-99
Аннотация
Частота почечно-клеточного рака (ПКР) неуклонно растет во всем мире в результате объективного роста числа таких пациентов, но также благодаря его выявлению на ранних стадиях при широком использовании неинвазивных методов диагностики (УЗИ, компьютерная томография и т.д.). Существенно улучшилась онкологическая выживаемость больных с ПКР и в такой ситуации возросло значение органосохраняющих операций для предотвращения развития или же замедления прогрессирования уже существующей хронической болезни почек (ХБП) – важнейшего фактора кардиоваскулярной заболеваемости и летальности.
Об авторах
А. М. Есаян
Санкт-Петербургский государственный медицинский университет им.акад. И.П.Павлова
Россия
Россия
Кафедра нефрологии и диализа
197022, Санкт-Петербург, ул. Л. Толстого, д. 17. корп. 54. Тел.: (812)-234-91-91
С.Х. Аль-Шукри
Санкт-Петербургский государственный медицинский университет им.акад. И.П.Павлова
Россия
кафедра урологии
Россия
кафедра урологии
М. С. Мосоян
Санкт-Петербургский государственный медицинский университет им.акад. И.П.Павлова
Россия
кафедра урологии
Россия
кафедра урологии
Список литературы
1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18 (3): 581-592
2. Foyil KV, Ames CD, Ferguson GG et al. (2008). Long-term changes in creatinine clearance after laparoscopic renal surgery. J Am Coll Surg 2008; 206: 511-515
3. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7(5): 245-257
4. Jemal A, Siegal R, Ward E. et al. Cancer Statistics. CA Cancer J Clin 2006; 59(4):225-249
5. Lang K, Danchenko N, Gondek K. et al. The burden of illness associated with renal cell carcinoma in the United States. Urol Oncol 2007; 25:368-375
6. Altekruse S, Kosary C, Krapcho M. et al. SEER Cancer Statistics Review, 1975- 2007, National Cancer Institute. Bethesda, MD, http:// seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
7. Тимофеев ИВ, Аксель ЕМ. Почечно-клеточный рак в России в 2008 году. Злокачественные опухоли (Русскоязычное издание журнала «Malignant tumors»). 2011; 1 (1): 6-10
8. Tsimafeyeu I, Aksel E. Renal Cell Carcinoma in the Russian Federation in 2008. Malign Tumours 2010;1:1-4
9. Ljungberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur Urol 2007; 51: 1502-1510
10. Kane CJ, Mallin K, Ritchey J et al. Renal cell cancer stage migration: analysis of the National Cancer Data base. Cancer 2008; 113 (1): 78-83
11. Cooperberg MR, Mallin K, Ritchey J et al. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol 2008; 179: 2131-2135
12. Woldrich JM, Mallin K, Ritchey J. et al. Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004. J Urol 2008; 179:1709-1713
13. Levin DC, Rao VM, Parker L. et al. Recent trends in utilization rates of abdominal imaging: the relative roles of radiologists and nonradiologist physicians. J Am Coll Radiol 2008
14. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology 2000; 56:58-62
15. Beisland C, Medby PC, Beisland HO. Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival. Scand J Urol Nephrol 2002; 36:414-418
16. Schlomer B, Figenshau RS, Yan Y, et al. Pathological features of renal neoplasms classified by size and symptomatology. J Urol 2006; 176(4 Pt 1):1317-1320, discussion 1320.
17. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006; 98:1331-1334
18. Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol 2006
19. Campbell SC, Novick AC, Belldegrun A. et al. Guideline for management of the clinical T1 renal mass. J Urol 2009; 182: 1271
20. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Onco 2000; 27: 115-123
21. Ljungberg B, Campbell SC, Cho HY. et al. The epidemiology of renal cell carcinoma. Eur Urol 2011; 60: 615-621
22. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281:1628-1631
23. Adams KF, Leitzmann MF, Albanes D. et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol 2008; 168: 268-277
24. Moyad MA. Review of potential risk factors for kidney (renal cell) cancer. Semin Urol Oncol 2001; 19(4):280-293
25. Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343(18):1305-1311
26. Setiawan VW, Stram DO, Nomura AM. et al. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 2007; 166: 932-940
27. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a largescale population-based cohort study in Japan. Arch Intern Med 2009; 166: 1871-1877
28. Go AS, Chertow GM, Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351 (13): 1296-1305
29. Волгина ГВ. Клиническая эпидемиология кардиоваскулярных нарушений при ХПН (Обзор литературы). Нефрология и диализ 2000; 2 (1): 25-32
30. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9 (3): 7-14
31. Есаян АМ, Карабаева АЖ, Каюков ИГ. Показатели эхокардиографии у больных с хронической болезнью почек и их динамика под влиянием терапии спиронолактоном. Нефрология 2008; 12 (1): 40-45
32. Herzog CA, Asinger RW, Berger AK. et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80(6): 572-586
33. Matas AJ, Simmons RL, Kjellstrand CM. et al. Increased incidence of malignancy during chronic renal failure. Lancet 1975; 19(1): 883-886
34. Stewart JH, Vajdoc CM, van Leeuwen MT. et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 2009; 24(10): 3225-3231
35. Liang JA, Sun LM, Yeh JJ. et al. The association between malignancy and end stage renal disease in Taiwan. Jpn J Clin Onco 2011; 41: 752-757
36. Mosconi G, Stalterii L, Centofanti F. et al. Incidence o cancer in kidney transplantation waiting list patients: a single center experience. Transplant Proc 2011; 43: 1003-1005
37. Weng PH, Hung KY, Huang HL. et al. Cancer specific mortality in chronic kidney disease: longitudinal follow up of a large cohort. Clin J Am Soc Nephrol 2011; 6 (5): 1121-1128
38. Wong G, Hayen A, Chapman JR. et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009; 20 (6): 1341-1350
39. Launay-Vacker V, Oudard S, Janus N. et al. Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in cancer patients and implications for anti cancer drug management. The renal insufficiency and anticancer medications study (IRMA). Cancer 2007; 110 (6): 1376-1384
40. Huang WC, Levey AS, Serio AM. et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumors: a retrospective cohort study. Lancet Oncol 2006; 7 (9): 735-740
41. Herr HW. Surgical management of renal tumors: a historical perspective. Urol Clin North Am 2008; 35(4):543-549
42. Russo P, Huang W. The medical and oncological rationale for partial nephrectomy for the treatment of T1 renal cortical tumors. Urol Clin North Am 2008; 35(4): 635-643
43. Segev DL, Muzaale AD, Caffo BS. et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 2010; 303(10):959-966
44. Bieniasz M, Domagala P, Kwiatkowski A. et al. The assessment of residual kidney function after living donor nephrectomy. Transplant Proc 2009; 41(1):91-92
45. Fehrman-Ekholm I, Duner F, Brink B. et al. No evidence of accelerated loss of kidney function in living kidney donors: results from a cross sectional follow up. Transplantation 2001; 72(3): 444-449
46. Goldfarb DA, Matin SF, Braun WE. et al. Renal outcome 25 years after donor nephrectomy. J Urol 2001; 166(6): 2043-2047
47. Kaplan C, Pasternack B, Shah H, Gallo G. Age-related incidence of sclerotic glomeruli in human kidneys. Am Pathol 1975; 80 (2): 227-234
48. Lau WK, Blute ML, Weaver AL. et al. Matched comparison of radical nephrectomy vs. nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contra lateral kidney. Mayo Clin Proc 2000; 75(12): 1236-1242
49. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 2002; 59(6): 816-820
50. Huang WC, Elkin EB, Levey AS. et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors-is there a difference in mortality and cardiovascular outcomes. J Urol 2009; 181(1): 55-62
51. Snow D, Bhayani S. Rapid Communication: Chronic Renal Insufficiency after Laparoscopic Partial Nephrectomy and Radical Nephrectomy for Pathologic T1a Lesions. Journal of Endourology 2008; 22(2): 337-342
Рецензия
Для цитирования:
Есаян А.М., Аль-Шукри С., Мосоян М.С. ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК И ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК: ВНИМАНИЕ К ОТДАЛЕННЫМ НЕОНКОЛОГИЧЕСКИМ ИСХОДАМ. Нефрология. 2012;16(4):94-99. https://doi.org/10.24884/1561-6274-2012-16-4-94-99
For citation:
Yesayan A.M., Al-Shukri S., Mosoyan M.S. RENAL CELL CARCINOMA AND CHRONIC KIDNEY DISEASE: ATTENTION TO DISTANT NON-ONCOLOGIC RESULTS. Nephrology (Saint-Petersburg). 2012;16(4):94-99. (In Russ.) https://doi.org/10.24884/1561-6274-2012-16-4-94-99
Просмотров:
314
Послать статью по эл. почте 